<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471548</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A1101</org_study_id>
    <nct_id>NCT01471548</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalating Study of TKI258</brief_title>
  <official_title>A Phase I Dose Escalating Study to Evaluate TKI258 Administered Orally on a 5 Days on/2days Off Schedule in Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of in this study is to assess the safety profile and estimate the maximum&#xD;
      tolerated dose of TKI258 in Japanese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of TKI258</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antineoplastic activity based on the RECIST criteria</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TKI258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <arm_group_label>TKI258</arm_group_label>
    <other_name>Dovitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any screening procedures&#xD;
&#xD;
          -  Advanced solid tumors&#xD;
&#xD;
          -  Agreement to remaining hospitalized&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Pregnant women. Male and female patients of reproductive potential must agree to&#xD;
             employ an effective method of birth control&#xD;
&#xD;
          -  Demonstrate the specific hematological /blood chemistry laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any investigational compound within 28 days prior to the first dose of&#xD;
             study drug or failure to have recovered from the side effects of such prior therapy&#xD;
&#xD;
          -  Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and&#xD;
             radiation therapy, within 28 days (with some exceptions)&#xD;
&#xD;
          -  Patients with CNS and/or leptomeningeal disease metastases&#xD;
&#xD;
          -  Presence or history of thromboembolic or cerebrovascular events&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Malabsorption syndrome or uncontrolled gastrointestinal toxicities&#xD;
&#xD;
          -  Patients known to be HIV- or HBV- or HCV- positive&#xD;
&#xD;
          -  Patients with acute or chronic uncontrolled infection&#xD;
&#xD;
          -  Patients who have undergone surgery with general anesthesia for any cause within 28&#xD;
             days prior to the first dose of study drug&#xD;
&#xD;
          -  Patients who have been receiving anticoagulant therapy&#xD;
&#xD;
          -  Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14&#xD;
             days prior to the first dose of study drug&#xD;
&#xD;
          -  Patients who have been administering concomitant medication which may prolong the QTc&#xD;
             interval&#xD;
&#xD;
          -  Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan&#xD;
&#xD;
          -  Patients with a large volume of ascitic and/or pleural fluid which requires drainage&#xD;
&#xD;
          -  Patients with any bone fractures&#xD;
&#xD;
          -  Deemed otherwise unsuitable by the investigator&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1241</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8745</url>
    <description>Results for CTKI258A1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>phase1</keyword>
  <keyword>TKI258</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

